# Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

> **NCT01814826** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** MLN4924
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01814826
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-10
- **Primary completion:** 2016-05-03
- **Final completion:** 2018-04-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814826, "Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01814826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*